Quintiles Transitional Holdings Inc. (NYSE:Q) Director Jack M. Greenberg sold 33,400 shares of Quintiles Transitional Holdings stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $108.07, for a total value of $3,609,538.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Quintiles Transitional Holdings Inc. (Q) opened at $103.51 on Friday. Quintiles Transitional Holdings Inc. has a 12 month low of $71.90 and a 12 month high of $110.67. The company has a current ratio of 1.22, a quick ratio of 1.22 and a debt-to-equity ratio of 1.29. The company has a market cap of $22,128.75, a P/E ratio of 23.91, a P/E/G ratio of 1.74 and a beta of 0.65.

Quintiles Transitional Holdings (NYSE:Q) last posted its quarterly earnings data on Thursday, October 26th. The medical research company reported $1.19 EPS for the quarter, beating the Zacks’ consensus estimate of $1.14 by $0.05. Quintiles Transitional Holdings had a net margin of 0.58% and a return on equity of 12.60%. The business had revenue of $2.02 billion for the quarter, compared to analyst estimates of $2.01 billion. During the same quarter last year, the business earned $1.00 earnings per share. The business’s revenue for the quarter was up 77.6% on a year-over-year basis. research analysts expect that Quintiles Transitional Holdings Inc. will post 4.62 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Jack M. Greenberg Sells 33,400 Shares of Quintiles Transitional Holdings Inc. (Q) Stock” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/10/jack-m-greenberg-sells-33400-shares-of-quintiles-transitional-holdings-inc-q-stock.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in shares of Quintiles Transitional Holdings by 2.2% during the second quarter. Vanguard Group Inc. now owns 12,789,723 shares of the medical research company’s stock valued at $1,144,680,000 after acquiring an additional 280,893 shares during the period. KBC Group NV increased its stake in shares of Quintiles Transitional Holdings by 53.3% during the second quarter. KBC Group NV now owns 18,959 shares of the medical research company’s stock valued at $1,697,000 after acquiring an additional 6,591 shares during the period. Key Square Capital Management LLC acquired a new position in shares of Quintiles Transitional Holdings during the second quarter valued at approximately $2,738,000. AXA increased its stake in shares of Quintiles Transitional Holdings by 85.4% during the second quarter. AXA now owns 251,830 shares of the medical research company’s stock valued at $22,539,000 after acquiring an additional 115,993 shares during the period. Finally, TIAA CREF Investment Management LLC increased its stake in shares of Quintiles Transitional Holdings by 5.4% during the second quarter. TIAA CREF Investment Management LLC now owns 832,571 shares of the medical research company’s stock valued at $74,515,000 after acquiring an additional 42,733 shares during the period. Institutional investors and hedge funds own 93.29% of the company’s stock.

A number of equities analysts have issued reports on the stock. Barclays PLC reissued an “overweight” rating and issued a $98.00 target price (up previously from $90.00) on shares of Quintiles Transitional Holdings in a report on Monday, July 17th. Mizuho cut shares of Quintiles Transitional Holdings from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a report on Thursday. Morgan Stanley raised their target price on shares of Quintiles Transitional Holdings from $96.00 to $121.00 and gave the stock an “overweight” rating in a report on Thursday. William Blair raised shares of Quintiles Transitional Holdings from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $70.10 to $93.42 in a report on Friday, August 4th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $94.00 target price on shares of Quintiles Transitional Holdings in a report on Friday, August 4th. Eleven equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $103.15.

Quintiles Transitional Holdings Company Profile

Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Insider Buying and Selling by Quarter for Quintiles Transitional Holdings (NYSE:Q)

Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.